BNP Paribas analyst Peter Verdult downgraded Sanofi (SNY) to Neutral from Outperform with a $50 price target The firm cites its revised pipeline assumptions for the downgrade. A “near-term rerating story is unlikely,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi’s Real‑World Teplizumab Study Targets Early Type 1 Diabetes Insights for Investors
- Sanofi says COVID-19 vaccine showed better tolerability than Moderna’s
- Trump names Erica Schwartz CDC Director
- Trump Trade: White House launches space nuclear initiative
- Drugmakers raised prices on hundreds of drugs, NBC News reports